Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$161.33 USD
+2.77 (1.75%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $161.08 -0.25 (-0.15%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
JNJ 161.33 +2.77(1.75%)
Will JNJ be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JNJ
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Other News for JNJ
DARZALEX FASPRO? (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
Q3’s Rising Stars: 3 Dow Stocks for Your Must-Watch List
A Closer Look at 14 Analyst Recommendations For Johnson & Johnson
Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges
Johnson & Johnson's Darzalex Faspro approved by FDA in multiple myeloma